Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Analysis of common oral and topical dermatologic medication price variation by source.

Boyko A, Smith GP.

Dermatol Online J. 2020 Jan 15;26(1). pii: 13030/qt8c2512rq.

2.

Noninvasive muscle activity imaging using magnetography.

Llinás RR, Ustinin M, Rykunov S, Walton KD, Rabello GM, Garcia J, Boyko A, Sychev V.

Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4942-4947. doi: 10.1073/pnas.1913135117. Epub 2020 Feb 18.

3.

Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD.

Cutter G, Veneziano A, Grinspan A, Al-Banna M, Boyko A, Zakharova M, Maida E, Pasic MB, Gandhi SK, Everts R, Cordioli C, Rossi S.

Mult Scler Relat Disord. 2020 Jan 20;40:101957. doi: 10.1016/j.msard.2020.101957. [Epub ahead of print]

PMID:
32028117
4.

Protective Allele for Multiple Sclerosis HLA-DRB1*01:01 Provides Kinetic Discrimination of Myelin and Exogenous Antigenic Peptides.

Mamedov A, Vorobyeva N, Filimonova I, Zakharova M, Kiselev I, Bashinskaya V, Baulina N, Boyko A, Favorov A, Kulakova O, Ziganshin R, Smirnov I, Poroshina A, Shilovskiy I, Khaitov M, Sykulev Y, Favorova O, Vlassov V, Gabibov A, Belogurov A Jr.

Front Immunol. 2020 Jan 17;10:3088. doi: 10.3389/fimmu.2019.03088. eCollection 2019.

5.

The Eupentacta fraudatrix transcriptome provides insights into regulation of cell transdifferentiation.

Boyko AV, Girich AS, Tkacheva ES, Dolmatov IY.

Sci Rep. 2020 Jan 30;10(1):1522. doi: 10.1038/s41598-020-58470-0.

7.

[Anti-NMDAR encephalitis associated with relapsing optic neuritis: a case report and differential diagnosis].

Belova AN, Grygorieva VN, Rasteryaeva MV, Ruina EA, Belova EM, Solovieva VS, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):137-146. doi: 10.17116/jnevro201911910137. Review. Russian.

PMID:
31934999
8.

[Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab].

Boyko OV, Choroshilova II, Petrov SV, Melnikov MV, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):120-127. doi: 10.17116/jnevro201911910120. Russian.

PMID:
31934997
9.

[The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].

Evdoshenko EP, Neofidov NA, Bakhtiyarova KZ, Davydovskaya MV, Kairbekova EI, Kolontareva YM, Malkova NA, Odinak MM, Popova EV, Sazonov DV, Stolyarov ID, Smagina IV, Fedyanin AS, Habirov FA, Khaibullin TI, Khachanova NV, Shchukin IA, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):110-119. doi: 10.17116/jnevro201911910110. Russian.

PMID:
31934996
10.

[The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis].

Boyko AN, Bakhtiyarova KZ, Dudin VA, Zaslavsky LG, Malkova NA, Parshina YV, Fedulov AS, Zinkina-Orikhan AV, Linkova YN, Ivanov RA, Chernovskaya TV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):100-109. doi: 10.17116/jnevro201911910100. Russian.

PMID:
31934995
11.

[Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety].

Boyko OV, Boyko AN, Yakovlev PA, Zinkina-Orikhan AV, Kotov SV, Linkova YN, Prakhova LN, Totolian NA, Shchur SG, Ivanov RA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):87-95. doi: 10.17116/jnevro20191191087. Russian.

PMID:
31934993
12.

[Comorbid pathology of the cardiovascular system in young patients with relapsing-remitting multiple sclerosis].

Traktirskaya OA, Popova EV, Lashch NY, Adasheva TV, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):72-80. doi: 10.17116/jnevro20191191072. Russian.

PMID:
31934991
13.

[Norepinephrine and intestinal microbiome in the early stages of demyelination: clinical-immunological parallels].

Sviridova AA, Kabaeva AR, Rogovskii VS, Kozhieva MK, Melnikov MV, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):28-34. doi: 10.17116/jnevro20191191028. Review. Russian.

PMID:
31934986
14.

Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity.

Kozhieva M, Naumova N, Alikina T, Boyko A, Vlassov V, Kabilov MR.

BMC Microbiol. 2019 Dec 30;19(1):309. doi: 10.1186/s12866-019-1685-2.

15.

Narrow-band periodically poled lithium niobate nonresonant optical parametric oscillator.

Wang L, Boyko AA, Schirrmacher A, Büttner E, Chen W, Ye N, Petrov V.

Opt Lett. 2019 Dec 1;44(23):5659-5662. doi: 10.1364/OL.44.005659.

PMID:
31774747
16.

[The pegylated form of interferon beta in the treatment of multiple sclerosis].

Melnikov MV, Kasatkin DS, Volkov AI, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(8):136-141. doi: 10.17116/jnevro2019119081136. Review. Russian.

PMID:
31626182
17.

Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group.

Boyko A.

Mult Scler. 2019 Oct 18:1352458519879622. doi: 10.1177/1352458519879622. [Epub ahead of print] No abstract available.

PMID:
31625816
18.

Genetic mapping of distal femoral, stifle, and tibial radiographic morphology in dogs with cranial cruciate ligament disease.

Healey E, Murphy RJ, Hayward JJ, Castelhano M, Boyko AR, Hayashi K, Krotscheck U, Todhunter RJ.

PLoS One. 2019 Oct 17;14(10):e0223094. doi: 10.1371/journal.pone.0223094. eCollection 2019.

19.

Imputation of canine genotype array data using 365 whole-genome sequences improves power of genome-wide association studies.

Hayward JJ, White ME, Boyle M, Shannon LM, Casal ML, Castelhano MG, Center SA, Meyers-Wallen VN, Simpson KW, Sutter NB, Todhunter RJ, Boyko AR.

PLoS Genet. 2019 Sep 16;15(9):e1008003. doi: 10.1371/journal.pgen.1008003. eCollection 2019 Sep.

20.

Conformational transitions in the active site of mycobacterial 2-oxoglutarate dehydrogenase upon binding phosphonate analogues of 2-oxoglutarate: From a Michaelis-like complex to ThDP adducts.

Wagner T, Boyko A, Alzari PM, Bunik VI, Bellinzoni M.

J Struct Biol. 2019 Nov 1;208(2):182-190. doi: 10.1016/j.jsb.2019.08.012. Epub 2019 Aug 30.

PMID:
31476368
21.

[Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis].

Tsareva EY, Favorova OO, Boyko AN, Kulakova OG.

Mol Biol (Mosk). 2019 Jul-Aug;53(4):574-599. doi: 10.1134/S0026898419040153. Review. Russian.

22.

Determination of S-adenosylmethionine and S-adenosylhomocysteine in blood plasma by UPLC with fluorescence detection.

Ivanov AV, Dubchenko EA, Kruglova MP, Virus ED, Bulgakova PO, Alexandrin VV, Fedoseev AN, Boyko AN, Grachev SV, Kubatiev AA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 15;1124:366-374. doi: 10.1016/j.jchromb.2019.06.032. Epub 2019 Jun 27.

PMID:
31295723
23.

Molecular Surveillance of HIV-1 Infection in Krasnoyarsk Region, Russia: Epidemiology, Phylodynamics and Phylogeography.

Neshumaev D, Lebedev A, Malysheva M, Boyko A, Skudarnov S, Ozhmegova E, Antonova A, Kazennova E, Bobkova M.

Curr HIV Res. 2019;17(2):114-125. doi: 10.2174/1570162X17666190618155816.

PMID:
31210113
24.

Loading Rate of Exogenous and Autoantigenic Determinants on Major Histocompatibility Complex Class II Mediates Resistance to Multiple Sclerosis.

Mamedov AE, Zakharova MY, Favorova OO, Kulakova OG, Boyko AN, Knorre VD, Vorobieva NA, Khurs EN, Kiselev IS, Baulina NM, Gabibov AG, Belogurov AA.

Dokl Biochem Biophys. 2019 Mar;485(1):115-118. doi: 10.1134/S1607672919020078. Epub 2019 Jun 14.

PMID:
31201628
25.

[Cancers and multiple sclerosis: risk of comorbidity and influence of disease modifying therapy].

Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):86-93. doi: 10.17116/jnevro20191192286. Russian.

PMID:
31156246
26.

[Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a].

Boyko AN, Bosenko LP, Vasilovskiy VV, Volkova LI, Zakharova MN, Kotov SV, Lekomtseva EV, Negrich TI, Parshina EV, Patrusheva OP, Prokopenko SV, Sazonov DV, Timchenko LV, Trinitatskiy YV, Khabirov FA, Khavunka MY, Chichanovskaya LV, Sherman MA, Ivanov RA, Lin'kova YN, Stukalina EY, Zinkina-Orikhan AV, Obukhova IG.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):73-85. doi: 10.17116/jnevro20191192273. Russian.

PMID:
31156245
27.

[Serotonergic system as a therapeutic target in multiple sclerosis].

Sviridova AA, Melnikov MV, Belousova OO, Rogovskii VS, Pashenkov MV, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):64-72. doi: 10.17116/jnevro20191192264. Russian.

PMID:
31156244
28.

[Anxiety and depressive psychopathological characteristics of patients with multiple sclerosis at different stages of disease].

Malygin VL, Boyko AN, Konovalova OE, Pahtusova EE, Dumbrova EV, Tishina IA, Malygin YV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):58-63. doi: 10.17116/jnevro20191192258. Russian.

PMID:
31156243
29.

[Influence of psychopathological factors and personality traits on the results of the study of quality of life in patients with multiple sclerosis].

Malygin VL, Boyko AN, Konovalova OE, Iskandirova AS, Dumbrova EV, Boyko OV, Malygin YV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):42-48. doi: 10.17116/jnevro20191192242. Russian.

PMID:
31156240
30.

[Clinical-epidemiological characteristics of multiple sclerosis and neuroopticomyelitis in the Central Asia].

Khaibullin TN, Kirillova EV, Bikbaev RM, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):12-17. doi: 10.17116/jnevro20191192212. Russian.

PMID:
31156235
31.

Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.

Cutter G, Veneziano A, Grinspan A, Al-Banna M, Boyko A, Zakharova M, Maida E, Pasic MB, Gandhi SK, Everts R, Cordioli C, Rossi S.

Mult Scler Relat Disord. 2019 Aug;33:13-21. doi: 10.1016/j.msard.2019.04.036. Epub 2019 May 9.

32.

Inbreeding depression causes reduced fecundity in Golden Retrievers.

Chu ET, Simpson MJ, Diehl K, Page RL, Sams AJ, Boyko AR.

Mamm Genome. 2019 Jun;30(5-6):166-172. doi: 10.1007/s00335-019-09805-4. Epub 2019 May 21.

33.

[Variability of the MIR196A2 Gene as a Risk Factor in Primary-Progressive Multiple Sclerosis Development].

Kiselev IS, Kulakova OG, Baulina NM, Bashinskaya VV, Popova EV, Boyko AN, Favorova OO.

Mol Biol (Mosk). 2019 Mar-Apr;53(2):282-289. doi: 10.1134/S0026898419020071. Russian.

34.

Simple nutrients bypass the requirement for HLH-30 in coupling lysosomal nutrient sensing to survival.

Murphy JT, Liu H, Ma X, Shaver A, Egan BM, Oh C, Boyko A, Mazer T, Ang S, Khopkar R, Javaheri A, Kumar S, Jiang X, Ory D, Mani K, Matkovich SJ, Kornfeld K, Diwan A.

PLoS Biol. 2019 May 14;17(5):e3000245. doi: 10.1371/journal.pbio.3000245. eCollection 2019 May.

35.

A novel variant m.641A>T in the mitochondrial MT-TF gene is associated with epileptic encephalopathy in adolescent.

Itkis Y, Krylova T, Pechatnikova NL, De Grassi A, Tabakov VY, Pierri CL, Aleshin V, Boyko A, Bunik VI, Zakharova EY.

Mitochondrion. 2019 Jul;47:10-17. doi: 10.1016/j.mito.2019.04.004. Epub 2019 Apr 19.

PMID:
31009750
36.

Cellular energetics and mitochondrial uncoupling in canine aging.

Nicholatos JW, Robinette TM, Tata SVP, Yordy JD, Francisco AB, Platov M, Yeh TK, Ilkayeva OR, Huynh FK, Dokukin M, Volkov D, Weinstein MA, Boyko AR, Miller RA, Sokolov I, Hirschey MD, Libert S.

Geroscience. 2019 Apr;41(2):229-242. doi: 10.1007/s11357-019-00062-6. Epub 2019 Apr 1.

37.

Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets.

Conway A, Mendel M, Kim K, McGovern K, Boyko A, Zhang L, Miller JC, DeKelver RC, Paschon DE, Mui BL, Lin PJC, Tam YK, Barbosa C, Redelmeier T, Holmes MC, Lee G.

Mol Ther. 2019 Apr 10;27(4):866-877. doi: 10.1016/j.ymthe.2019.03.003. Epub 2019 Mar 7.

PMID:
30902585
38.

MiRNAs from DLK1-DIO3 Imprinted Locus at 14q32 are Associated with Multiple Sclerosis: Gender-Specific Expression and Regulation of Receptor Tyrosine Kinases Signaling.

Baulina N, Osmak G, Kiselev I, Popova E, Boyko A, Kulakova O, Favorova O.

Cells. 2019 Feb 8;8(2). pii: E133. doi: 10.3390/cells8020133.

39.

Reference assembly and gene expression analysis of Apostichopus japonicus larval development.

Boyko AV, Girich AS, Eliseikina MG, Maslennikov SI, Dolmatov IY.

Sci Rep. 2019 Feb 4;9(1):1131. doi: 10.1038/s41598-018-37755-5.

40.

Variants of Mitochondrial Genome and Risk of Multiple Sclerosis Development in Russians.

Kozin MS, Kulakova OG, Kiselev IS, Balanovsky OP, Boyko AN, Favorova OO.

Acta Naturae. 2018 Oct-Dec;10(4):79-86.

41.

Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.

Kiselev I, Bashinskaya V, Baulina N, Kozin M, Popova E, Boyko A, Favorova O, Kulakova O.

Mult Scler Relat Disord. 2019 Apr;29:130-136. doi: 10.1016/j.msard.2019.01.033. Epub 2019 Jan 24.

PMID:
30711878
42.

The effects of Z56822977 on biosynthesis of serotonin in the brain of rats in the conditions of MSG-induced obesity.

Konopelniuk V, Falalyeyeva T, Tsyryuk O, Savchenko Y, Kobyliak N, Prybytko I, Kovalchuk O, Boyko A, Arkhipov VV, Moroz Y, Ostapchenko L.

Endokrynol Pol. 2018;69(5):536-544. doi: 10.5603/EP.2018.0058.

43.
44.

International consensus on quality standards for brain health-focused care in multiple sclerosis.

Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G.

Mult Scler. 2019 Nov;25(13):1809-1818. doi: 10.1177/1352458518809326. Epub 2018 Nov 1.

45.

Direct-to-consumer DNA testing of 6,000 dogs reveals 98.6-kb duplication associated with blue eyes and heterochromia in Siberian Huskies.

Deane-Coe PE, Chu ET, Slavney A, Boyko AR, Sams AJ.

PLoS Genet. 2018 Oct 4;14(10):e1007648. doi: 10.1371/journal.pgen.1007648. eCollection 2018 Oct.

46.

Antimicrobial action of calprotectin that does not involve metal withholding.

Besold AN, Culbertson EM, Nam L, Hobbs RP, Boyko A, Maxwell CN, Chazin WJ, Marques AR, Culotta VC.

Metallomics. 2018 Dec 12;10(12):1728-1742. doi: 10.1039/c8mt00133b.

47.

[Issues of the current terminology in multiple sclerosis].

Boyko AN, Guseva MR, Khachanova NV, Gusev EI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):121-127. doi: 10.17116/jnevro2018118082121. Russian.

PMID:
30160680
48.

[Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report].

Boyko OV, Khoroshylova II, Petrov SV, Lush NY, Guseva ME, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):116-120. doi: 10.17116/jnevro2018118082116. Russian.

PMID:
30160679
49.

[The risk of ischemic stroke in patients with multiple sclerosis].

Sivertseva SA, Prilenskaya AM, Sivertsev MY, Bazhukhin DV, Smirnova NF, Guseva ME, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):88-94. doi: 10.17116/jnevro201811808288. Review. Russian.

PMID:
30160674
50.

[Provision of alemtuzumab safety is one of the main components of pharmacovigilance].

Khachanova NV, Bakhtiyarova KZ, Boyko AN, Vlasov YV, Davydovskaia MV, Evdoshenko EP, Zakharova MN, Malkova NA, Sivertseva SA, Spirin NN, Stolyarov ID, Schmidt TE, Khabirov FA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):82-87. doi: 10.17116/jnevro201811808282. Russian.

PMID:
30160673

Supplemental Content

Support Center